• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Nymox AlzheimAlert(TM) Independent Clinical Trial Data To Be Presented at the XXVIIIth International Congress of Clinical Neurophysiology

Posted on: Wednesday, 23 August 2006, 12:00 CDT

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that independent clinical trial results from studies of the Company's AlzheimAlert (TM) test will be presented at the XXVIIIth International Congress of Clinical Neurophysiology in Edinburgh, Scotland on September 11, 2006. The presentation will concern the use of the AlzheimAlert(TM) test in the diagnosis of mild cognitive impairment in the elderly. The authors of the paper include Ira Goodman of Orlando Regional Healthcare System, Stephen Flitman of 21st Century Neurology, Phoenix AZ, Kevin Xie of Centra Care Clinic, St. Cloud MN, Alireza Minagar of Louisiana State University Health Sciences Center, Shreveport LA and Ralph Richter of University of Oklahoma, Tulsa OK.

The AlzheimAlert(TM) test is a urine based diagnostic aid for Alzheimer's disease. It is the only proven accurate non-invasive AD test technology available. The test has the CE Mark, allowing it to be marketed in Europe, and is CLIA certified as a laboratory test service which is available in the U.S. Nymox currently has numerous initiatives underway for the AlzheimAlert(TM) testing technology, including marketing and distribution overseas, and global product development.

There are an estimated 4.5 million people with Alzheimer's disease in the United States alone; by 2050 this number is projected to increase almost three times to 13.2 million. Worldwide estimates of the current number of people with Alzheimer's disease range from 15 to 20 million. The annual national direct and indirect costs of caring for Alzheimer patients in the U.S. alone are estimated at $100 billion. The human toll on patients, families and caregivers is incalculable.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Source: Business Wire

More News in this Category